Johnson & Johnson $JNJ Stock Holdings Lowered by Richard Bernstein Advisors LLC

Hedge fund reduces stake in pharmaceutical giant by over 50%

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Richard Bernstein Advisors LLC, a major investment firm, has significantly reduced its position in Johnson & Johnson (NYSE: JNJ) by 53.5% during the third quarter, according to a recent SEC filing. The fund now owns 23,291 shares of the company's stock, down from 50,045 shares previously.

Why it matters

This move by a prominent investment firm could signal a shift in sentiment around Johnson & Johnson, one of the world's largest and most diversified healthcare companies. Investors will be watching to see if other major funds follow suit or if this is an isolated portfolio adjustment.

The details

According to the filing, Richard Bernstein Advisors sold 26,754 shares of Johnson & Johnson stock during the third quarter. The firm's remaining position is valued at $4.3 million. Johnson & Johnson is a diversified healthcare company with operations in pharmaceuticals, medical devices, and consumer products. The company has faced some legal challenges in recent years related to its talcum powder and opioid products, which may have contributed to the hedge fund's decision to reduce its exposure.

  • Richard Bernstein Advisors LLC filed the 13F report disclosing the reduced Johnson & Johnson holdings on March 10, 2026.

The players

Richard Bernstein Advisors LLC

An investment management firm that provides asset allocation, equity, and fixed income investment solutions to institutional and private clients.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Johnson & Johnson holdings by a major investment firm like Richard Bernstein Advisors could signal broader uncertainty around the company's future prospects, particularly as it navigates legal challenges and a shifting healthcare landscape. Investors will be closely watching to see if this is an isolated move or the start of a broader trend.